RecruitingLipidemiaType 2 Diabetes (T2DM)Metabolic Syndrome (MetS)

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Eligible age

18+ yrs

Accepts

All genders

Locations

13 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and/or Type 2 Diabetes Mellitus.

Sponsor: NewAmsterdam Pharma

You may qualify if…

✓ fasting serum LDL-C ≥ 70 mg/dL (≥1.81 mmol/L)
✓ Have fasting TG ≥150 mg/dL (≥1.7 mmol/L) and \<400 mg/dL (\<4.5 mmol/L)
✓ Know diagnosis of T2DM OR have metabolic syndrome defined as fasting TG ≥150 mg/dL (≥1.7mmol/L) and \<400 mg/dL (\<4.5 mmol/L) and at least 2 risk factors
✓ Are on stable guideline-recommended lipid-lowering therapy
✓ Estimated glomerular filtration rate ≥15 mL/min/1.73 m2

You may not qualify if…

✕ Have current or any previous history of New York Heart Association class III or IV heart failure or left ventricular ejection fraction \<30%
✕ Have been hospitalized for heart failure within 5 years prior to Screening
✕ Have uncontrolled severe hypertension
✕ Have a formal diagnosis of homozygous familial hypercholesterolemia
✕ HbA1c ≥10.0% (≥0.100 hemoglobin fraction) or a fasting glucose ≥270 mg/dL (≥15.0 mmol/L) at Screening
✕ active liver disease